Determinants of orphan drug health technology assessment in South Korea: an empirical analysis

The pricing of orphan drugs in South Korea is predominantly influenced by external reference pricing. Drugs targeting smaller patient populations tend to be priced higher. This finding can guide policymakers, pharmaceutical companies, and healthcare providers in their efforts to balance patient accessibility with the sustainable development of orphan drugs and the financial sustainability of public health insurance.